Charles River and ATEM partner to accelerate drug discovery efforts

By Jane Byrne contact

- Last updated on GMT

© GettyImages/Monty Rakusen
© GettyImages/Monty Rakusen

Related tags: Drug discovery, AAV, gene therapies

Charles River and ATEM Structural Discovery (ATEM) are collaborating to provide access to cryo-electron microscopy (cryo-EM), a technique that visualizes molecules and proteins in atomic resolution to determine their 3D shape.

The alliance has the potential to significantly accelerate drug discovery efforts, according to the partners.

Charles River’s clients gain access to ATEM’s cryo-EM platform to support their drug discovery work, potentially getting early insights into how lead candidates interact with their intended disease target, allowing for more informed prioritization and optimization of lead candidates.

ATEM’s technology directly images vitrified biological macromolecules in single-particle experiments at high resolution.

“Subsequently, reconstructed coulomb potential maps then allow the precise modeling of 3D atomic coordinates that elucidate the target structure. This leads to the identification of novel distinct binding sites and significantly improves the discovery of drug candidates.”

Fast turnaround times

Due to the minimal amount of samples needed, fast turnaround times and statistical certainty, cryo-EM will also support the analysis of adeno-associated virus (AAV) vector-based gene therapies, as well as novel mRNA and plasmid-based drugs, making it a powerful orthogonal tool to support both quality control and R&D efforts, said the companies. 

“Cryo-EM will expand the portfolio of drug targets that we can generate a 3D understanding of, enhance our knowledge of how to modulate these targets and enable computational drug design for more of our client projects.

“ATEM’s cryo-EM expertise is a perfect complement to our established x-ray crystallography platform,”​ said Grant Wishart, director CADD & structural biology, discovery, at Charles River.


Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us


View more